CN108658963A - A kind of antitumor drug acting on tubulin - Google Patents
A kind of antitumor drug acting on tubulin Download PDFInfo
- Publication number
- CN108658963A CN108658963A CN201810637536.2A CN201810637536A CN108658963A CN 108658963 A CN108658963 A CN 108658963A CN 201810637536 A CN201810637536 A CN 201810637536A CN 108658963 A CN108658963 A CN 108658963A
- Authority
- CN
- China
- Prior art keywords
- tubulin
- compound
- antitumor drug
- yls
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses a kind of antitumor drug acting on tubulin, structural formula isWherein, R1、R2It is independently selected from H, OH or F.Find that there is good tubulin inhibitory activity by the test of tubulin polymerization assays kit, it can be obtained by 7402 transplanted human hepatocellular carcinoma Experimental model of small mice of Bel, the compounds of this invention has anti-tumor drug activity, can be used for antitumor drug and carries out more deep research and development.
Description
Technical field
The invention belongs to drug design and synthesis fields, are related to a kind of antitumor drug acting on tubulin.
Technical background
Cancer cell is maximum frequent and uncontrolled difference lies in the Mitotic abnomality of cancer cell with normal cell.Cancer
Dynamic circulation (polymerize and depolymerization) between the schizogamy process of cell Showed Very Brisk and tubulin/micro-pipe in the cell cycle
There is close contact.Therefore, by tubulin polymerization during inhibiting tumour cell division at micro-pipe, or inhibit micro-pipe
Depolymerization is tubulin, will cause mitosis that can not carry out or stagnate, and the interruption of cell mitogen process will be to swollen
Oncocyte generates the influence of bigger, and growth is made to be suppressed and induce the apoptosis of tumour cell, what final inducing cell tune was died
Occur, to achieve the purpose that inhibit tumour cell increment growth.
Having now been found that a large amount of natural, synthesis and semi-synthetic compound have influences microtubule system, interferes it normal
The effect of function because of most of its energy and tubulin binding, therefore is referred to as Antitubulin.These tubulins inhibit
Agent has had a wide range of applications in terms of medicine, such as antitumor, antimycotic, expelling parasite, and tubulin has become research and opens
The important target spot of new type antineoplastic medicine is sent out, Antitubulin, which also has become, clinically uses effective important antineoplastic
Object.The mechanism of action of such inhibitor is, by being acted on micro-pipe, to inhibit tubulin poly- in the tumour cell quickly divided
Conjunction prevents spindle from being formed, or promotes tubulin polymerization, and spindle is prevented to be interfered thin from reverting to micro-pipe net again
The positive eumitosis process of born of the same parents makes cell mitogen process interrupt, and is stagnated in the phase, is adjusted so as to cause tumour cell
It dies, plays antitumor action.
Colchicin is a kind of Tropolones biology extracted from the seed and its bulb of liliaceous plant colchicum
Alkali.Colchicin can be incorporated into the colchicin site on tubulin, and α tubulins is made to deform with beta tubulin,
Make tubulin be assembled into micro-pipe this process to be blocked, to make the formation of spindle be obstructed, makes Mitosis arrest
And causes cell to generate tune and die.Colchicin may also interfere with the protein metabolism process of tumour cell, inhibit the work of RNA polymerases
Power, and the transport process of the synthesis and amino acid of cell membrane lipoids on cell membrane is blocked, to induce a variety of entity tumors
Natural death of cerebral cells.Experiment finds that colchicin is significant in efficacy to breast cancer, leukaemia, cutaneum carcinoma, to cervix cancer, the cancer of the esophagus, lung
Cancer also has certain curative effect.Research recently finds that colchicin has apparent inhibition and induction to adjust growth of glioma cells in vitro
The effect of dying.Clinically colchicin is usually used in treating acute gout, arthralgia, familial Mediterranean fever, hepatic sclerosis etc., but because
Toxicity is too big and less for treating tumour.
Invention content
One of the objects of the present invention is to provide a kind of compound, structural formula I is as follows：
Wherein, R1、R2It is independently selected from H, OH or F.
Further, Formula I is selected from：
Further, above compound or its pharmaceutically acceptable salt as Antitubulin answering in drug
With.
Further, the purposes of above-mentioned compound or its pharmaceutically acceptable salt in the preparation of antitumor drugs.
Another object of the present invention is to provide a kind of synthetic routes of the compound to be：
Further, specific synthesis step is：
1) 6- (1H- pyrazol-1-yls) niacin (compound 1) undergoes coupling reaction to produce 6- (1H- pyrazoles -1- with benzyl bromide
Base) nicotinic acid benzyl ester (compound 2)；
2) with nitrating agent nitration reaction occurs for compound 2, generates 2- nitros -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
(compound 3)；
3) compound 3 issues raw reduction reaction in suitable reducing condition, generates 2- amino -6- (1H- pyrazol-1-yls) cigarette
Acid benzyl ester (compound 4)；
4) compound 4 generates corresponding amides product with corresponding acyl chloride reaction.
Further, the nitrating agent in the step 2) has a concentrated nitric acid, fuming nitric aicd, the mixed acid of nitric acid and sulfuric acid with
And dinitrogen pentoxide etc., the preferred mixed acid of nitric acid and sulfuric acid.
Further, the nitro restoring method in the step 3) has ferrous acid reduction method, catalytic hydrogen reduction and hydration
Hydrazine reduction method, preferably ferrous acid reduction method.
Obviously, the above according to the present invention is not departing from this hair according to the ordinary technical knowledge and means of this field
Under the premise of bright above-mentioned basic fundamental thought, the modification, replacement or change of other diversified forms can also be made.
Specific implementation mode
Embodiment 1：The synthesis of 2- (isoxazole -5- formamido groups) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
1, the synthesis of 6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
6- (1H- pyrazol-1-yls) niacin (compound 1) (4.86g, 25.7mmol) is dissolved in anhydrous DMF (100mL),
Under argon atmosphere, potassium carbonate (10.66g, 77.1mmol) and benzyl bromide (13.19g, 77.1mmol) are added to above-mentioned solution
In, it then stirs mixture 15 hours and is transferred in distilled water (150mL), mixture is extracted three times with diethyl ether (100mL).
Combined extract is washed, magnesium sulfate drying with distilled water (100mL), and be concentrated under vacuum using rotary evaporator, obtained
To crude product 6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester (compound 2), the recrystallization purifying in hexane of crude Compound 2 obtains
Pure compound 2, white solid, 6.39g, yield 89%.1H-NMR(400MHz,CDCl3)δ:5.22(s,2H),6.53(t,
1H),7.30-7.36(m,6H),7.77(d,1H),8.47(d,1H),8.57(d,1H),9.19(s,1H).13C-NMR
(125MHz,CDCl3)δ:67.02,107.94,110.56,127.13,128.16,128.19,129.01,130.95,
137.56,139.64,141.01,150.63,153.33,163.97.LC-MS(ESI,pos,ion)m/z:280[M+H].
2, the synthesis of 2- nitros -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
Compound 2 (6.39g, 22.88mmol) is dissolved in chloroform (100mL), under condition of ice bath (10 DEG C or so), by
It is added dropwise to the mixed acid solution that 65% concentrated nitric acid (2.5mL, 32.03mmol) and 98% concentrated sulfuric acid (2.5mL, 38.90mmol) are made into.
It after being added dropwise, is stirred to react at 10 DEG C about 4 hours, TLC monitors reaction end.After completion of the reaction, reaction solution is concentrated under reduced pressure
It to doing, is gradually poured into ice water, it is neutral to be adjusted to pH with sodium carbonate, filters, obtains light yellow product 2- nitros -6- (1H- pyrroles
Azoles -1- bases) nicotinic acid benzyl ester (compound 3), 6.68g, yield 90%.1H-NMR(400MHz,CDCl3)δ:5.22(s,2H),6.56
(t,1H),7.30-7.36(m,6H),7.88(d,1H),9.21(d,1H),9.24(d,1H).13C-NMR(125MHz,CDCl3)
δ:67.02,107.94,116.41,127.13,128.16,128.19,129.01,132.84,137.56,141.01,
147.15,150.20,153.00,168.45.LC-MS(ESI,pos,ion)m/z:325[M+H].
3, the synthesis of 2- amino -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
Compound 3 (6.68g, 20.60mmol) and ammonium chloride (0.55g, 10.30mmol) are added to 95% second successively
In alcohol (150mL), glacial acetic acid (0.5mL, 2.06mmol) is added, is warming up to 80 DEG C, reaction after ten minutes, is gradually added into also in batches
Former iron powder (9.23g, 164.8mmol), reacts after about 3 hours and finishes, and TLC monitors reaction end.It is filtered while hot to remove dereaction
Iron cement in liquid.Iron cement filter cake is boiled 1 hour under reflux conditions with 95% ethyl alcohol, then is filtered while hot.3 times repeatedly, merge filter
Liquid is concentrated to dryness, and 45 DEG C of vacuum obtains gray solid 2- amino -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester (compound 4),
5.52g, yield 91%.1H-NMR(400MHz,CDCl3)δ:1.28(s,2H),5.22(s,2H),6.53(t,1H),7.30-
7.35(m,6H),7.69(d,1H),7.78(d,1H),8.26(d,1H).13C-NMR(125MHz,CDCl3)δ:67.02,
101.48,107.94,112.66,127.13,128.16,128.19,129.01,137.56,141.01,141.91,152.73,
158.76,171.44.LC-MS(ESI,pos,ion)m/z:295[M+H].
4, the synthesis of 2- (isoxazole -5- formamido groups) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
Compound 4 (5.52g, 18.76mmol) is added in absolute ethyl alcohol (150mL), isoxazole-is then gradually added into
5- formyl chlorides (28.36mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 6 hours, TLC monitors reaction end.It will be anti-
It after answering liquid to stand cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product 2- (isoxazole -5- formyls
Amino) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester, 6.28g, yield 86%.1H-NMR(400MHz,CDCl3)δ:5.31(s,
1H),6.67(dd,1H),7.18(d,1H),7.28-7.37(m,5H),7.81(d,1H),7.89(d,1H),7.93(d,1H),
8.13(d,1H),8.37(d,1H).13C-NMR(125MHz,CDCl3)δ:66.92,101.25,108.93,109.84,
110.64,125.88,128.35,128.61,135.66,140.54,143.55,145.69,153.98,156.06,160.7,
164.24,166.02.LC-MS(ESI,pos,ion)m/z:390[M+H]。
Embodiment 2：The synthesis of 2- (4- hydroxyls-isoxazole -5- formamido groups) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
Compound 4 (5.52g, 18.76mmol) is added in absolute ethyl alcohol (150mL), 4- hydroxyls-are then gradually added into
Isoxazole -5- formyl chlorides (28.36mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 6 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product 2- (4- hydroxyls
Base-isoxazole -5- formamido groups) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester, 6.24g, yield 82%.LC-MS(ESI,pos,
ion)m/z:406[M+H]。
Embodiment 3：The synthesis of 2- (the fluoro- isoxazole -5- formamido groups of 3-) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester
Compound 4 (5.52g, 18.76mmol) is added in absolute ethyl alcohol (150mL), it is fluoro- different to be then gradually added into 3-
Oxazole -5- formyl chlorides (28.36mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 6 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtaining white solid product 2-, (3- is fluoro-
Isoxazole -5- formamido groups) -6- (1H- pyrazol-1-yls) nicotinic acid benzyl ester, 6.80g, yield 89%.LC-MS(ESI,pos,ion)
m/z:408[M+H]。
Test example 1：Tubulin inhibitory activity
With reference to the Tubulin PolymerizationAssay Kit (tubulin polymerizations point of Cyroskeleton companies
Analyse kit) specification, it is operated and is measured.With 80mM PIPES pH 6.9,0.5mM EGTA, 2mM MgCl2, 1mM
The glycerol of Mg GTP and 10% at 3mg/ml cow brain tissue tubulin solution.The tubulin solution 100 μ L are taken, it is fast
Speed is added in 96 orifice plates containing various concentration untested compound and colchicin (colchicine), and control wells are added identical
Final concentration DMSO (<0.5%).37 DEG C are set, 5%CO2Lower incubation, initiated polymerization.With multi-function microplate reader measure its
Wavelength is the absorption value of 355nm, primary per 3min readings, 45min is surveyed altogether, with prism Software on Drawing tubulin polymerization power
Curve is learned, and acquires IC50(when a concentration of its original concentration half of tubulin, the concentration for the compound being added).
IC of 1 compound of table to tubulin50
| Compound | IC50(nM) |
| colchicine | 1782 |
| COLC-301 | 87 |
| COLC-302 | 81 |
| COLC-303 | 89 |
| COLC-304 | 75 |
| COLC-305 | 81 |
| COLC-306 | 86 |
| COLC-307 | 92 |
It can be obtained by upper table, listed compound tubulin inhibitory activity IC in table50Value is respectively less than
It is lower to illustrate that compound listed in table reaches the concentration needed when tubulin half inhibits by colchicine.Confirm this
The prepared compound of invention has tubulin inhibitory activity, can carry out antitumor drug as Antitubulin
Exploitation.
Embodiment 2：Bel-7402 transplanted human hepatocellular carcinoma mouse models are studied
One, human liver cancer nude mouse xenotransplant cancer model is established
SPF grades of Balb/c nude mices, male, 4 week old, people's Bel-7402 liver cancer cells nude mice model tumor formations of learning from else's experience, then through naked
2 more than generation tumor mass of mouse passage, is cut into about 2*2*2mm, and it is subcutaneous to be inoculated in nude mice armpit using trochar, establishes human liver cancer nude mice
Heteroplastic transplantation cancer model.
Two, dosage regimen
With the length and width of each animal tumor of vernier caliper measurement, by formula：V=1/2*ab2Knurl product is calculated, waits for that knurl is accumulated
It grows to about 100mm3Start to be administered, all animals are randomly divided into model group, positive drug capecitabine group (400mg/ by knurl product
Kg), medicine group (100mg/kg) to be measured, every group 8, each group gastric infusion, dosage is l0ml/kg, 1 time/d, successive administration
14d。
Three, knurl weight and tumour inhibiting rate
Strip tumor mass within 16th day, assay balance claims knurl weight, calculates tumour inhibiting rate as follows.
Tumour inhibiting rate %=(model group average knurl weight-administration group average knurl weight)/model group average knurl weight * 100%.
Data analysis is carried out to testing result using 5 data processing softwares of GraphPadPrism.
Four, knurl weight and tumour inhibiting rate
The different group Bel-7402 transplanted human hepatocellular carcinoma mouse knurl weights of table 2 and tumour inhibiting rate (N=8)
Note：* the P compared with model group<0.05
As can be seen from the above table, compared with model group, the equal conspicuousness of other each group knurl weights reduces, the listed present inventionization in table
It closes object (100mg/kg) tumour inhibiting rate and is higher than capecitabine (400mg/kg), illustrate that the compounds of this invention dosage has in 100mg/kg
There is good tumors inhibition activity.It can be obtained by Bel-7402 transplanted human hepatocellular carcinomas Experimental model of small mice, the compounds of this invention tool
There is anti-tumor drug active, can be used for antitumor drug and carry out more deep research and development.
The above is only a preferred embodiment of the present invention, it is noted that come for those of ordinary skill in the art
It says, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should be regarded as
The content that the present invention is covered.
Claims (4)
1. a kind of compound, which is characterized in that its structural formula I is as follows：
Wherein, R1、R2It is independently selected from H, OH or F.
2. compound as described in claim 1, characterized in that be further selected from：
3. compound as described in claim 1 or its pharmaceutically acceptable salt are as Antitubulin in drug
Using.
4. the purposes of compound as described in claim 1 or its pharmaceutically acceptable salt in treatment is antitumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810637536.2A CN108658963A (en) | 2018-06-20 | 2018-06-20 | A kind of antitumor drug acting on tubulin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810637536.2A CN108658963A (en) | 2018-06-20 | 2018-06-20 | A kind of antitumor drug acting on tubulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108658963A true CN108658963A (en) | 2018-10-16 |
Family
ID=63772145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810637536.2A Withdrawn CN108658963A (en) | 2018-06-20 | 2018-06-20 | A kind of antitumor drug acting on tubulin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108658963A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726196A (en) * | 2002-12-11 | 2006-01-25 | 西托匹亚有限公司 | Pyrazine-based tubulin inhibitors |
| CN1890218A (en) * | 2003-12-03 | 2007-01-03 | 西托匹亚研究有限公司 | Tubulin inhibitors |
| CN101610763A (en) * | 2006-12-15 | 2009-12-23 | 诺瓦提斯公司 | Heterocyclic compound and its application method |
-
2018
- 2018-06-20 CN CN201810637536.2A patent/CN108658963A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726196A (en) * | 2002-12-11 | 2006-01-25 | 西托匹亚有限公司 | Pyrazine-based tubulin inhibitors |
| CN1890218A (en) * | 2003-12-03 | 2007-01-03 | 西托匹亚研究有限公司 | Tubulin inhibitors |
| CN101610763A (en) * | 2006-12-15 | 2009-12-23 | 诺瓦提斯公司 | Heterocyclic compound and its application method |
Non-Patent Citations (2)
| Title |
|---|
| SHU-FU WANG ET AL: ""Synthesis, biological evaluation and 3D-QSAR studies of novel 5-phenyl-1H-pyrazol cinnamamide derivatives as novel antitubulin agents"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
| 施赛健 等: "抗肿瘤多药耐药微管蛋白调节剂的研究进展", 《药学实践杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106916101B (en) | NAMPT/HDAC double-target inhibitor and preparation method thereof | |
| JP6890097B2 (en) | EZH2 inhibitor for treating lymphoma | |
| US20200131191A1 (en) | Atropisomerism for increased kinase inhibitor selectivity | |
| CN103030597B (en) | Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor | |
| CN102838590A (en) | Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs | |
| JP2013530130A (en) | Heteroaryl (alkyl) dithiocarbamate compounds, their preparation and use | |
| CN101195597A (en) | 1-substituted-4,4-2 substituted thiosemicarbazide compounds, production method and uses of the same | |
| CN107090000B (en) | A kind of derivative of 7 fatty acid of benzo borazol and its preparation and purposes | |
| CN109467549A (en) | Quinoline replaces chalcone compounds, preparation method and the usage | |
| CN107311905B (en) | A kind of nopinone thiosemicarbazone derivative and its preparation method and application | |
| US8349854B2 (en) | Salts of 4-aniline quinazoline derivative | |
| CN102746306A (en) | Allopurinol derivative and preparation method and application thereof | |
| CN108033950B (en) | EGFR tyrosine kinase inhibitor BF with anti-tumor activity3- AZD9291 and its preparation method and application | |
| CN104557913A (en) | Pyridopyrimidine compounds as well as preparation method and application thereof | |
| CN102746308B (en) | Allopurinol derivative and preparation method and application thereof | |
| KR100817808B1 (en) | Cancer treatment | |
| CN108658963A (en) | A kind of antitumor drug acting on tubulin | |
| CN108690004A (en) | A kind of antitumor drug acting on tubulin | |
| CN108675992A (en) | A kind of antitumor drug acting on tubulin | |
| CN108707147A (en) | A kind of novel tubulin inhibitor and its application in antitumor drug | |
| CN108675997A (en) | A kind of novel tubulin inhibitor and its application in antitumor drug | |
| CN108864053A (en) | A kind of novel tubulin inhibitor and its application in anti-tumor drug | |
| CN108218855A (en) | A kind of novel tubulin inhibitor and its application in antitumor drug | |
| CN110590681B (en) | Novel quinazoline ketone compound and preparation method and application thereof | |
| CN107513040A (en) | Substitute the preparation of benzo pyridine compound and the application of molecular targeted anti-tumor medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181016 |